The Clinical Imperative: High-Sensitivity Troponin-I in UK Pathways

High-sensitivity cardiac troponin I assays are now fundamental to UK clinical pathways for suspected myocardial infarction (MI). NICE guidance explicitly supports the use of high-sensitivity troponin tests (with precise analytical performance) for early rule-out of non-ST-segment elevation myocardial infarction (NSTEMI). These assays can detect troponin at very low concentrations with high precision, enabling clinicians to confidently stratify patients at presentation and over short serial intervals.

Traditional laboratory measurement has been the cornerstone of this strategy. However, laboratory turnaround times even when well-optimised can delay clinical decision-making by up to several hours. High-sensitivity POC testing shifts this paradigm by bringing the assay to the patient’s bedside, reducing time to result, and supporting faster clinical decisions.

Why Point-of-Care High-Sensitivity Matters

Point-of-care hs-cTnI testing offers several practical benefits in acute care settings:

• * Faster Results: By measuring hs-cTnI near the patient, results can be available far sooner than standard lab processing, helping accelerate diagnostic pathways and streamlining patient flow in busy Emergency Departments (EDs).
• * Clinical Decision Support: Rapid hs-cTnI results can support safe early rule-out protocols and targeted evaluation of ACS, potentially reducing unnecessary admissions and freeing resources for patients who need them most.
• * Flexible Deployment: POC testing can also be invaluable in settings where access to central lab facilities is limited, such as minor injury units, rural hospitals, or urgent community care hubs.
• 
  

Recent evidence and expert thought leadership suggest that as POC assays increasingly approach the analytical sensitivity and precision of central laboratory systems, their role in clinical pathways will expand further - from “rule-in” support to meaningful “rule-out” tools.

At the forefront of EMR-connected, rapid immunoassay testing is the FIAPro Immunofluorescence Analyser : a compact, high-performance point-of-care device. 

Key advantages include:

Fluorescence immunoassay technology capable of delivering sensitive quantitative results across a range of biomarkers in whole blood, serum or plasma.

• * Clinical speed and simplicity: Designed for POC environments, the analyser is CE-marked, easy to use, and suitable for rapid testing where minutes matter.
• Android-based interface with built-in connectivity options (e.g., LIS/HIS), facilitating seamless data flow into patient records.
• * Connectivity and workflow integration:  Android-based interface with built-in connectivity options (e.g., LIS/HIS), facilitating seamless data flow into patient records. 
• * Adaptable platform: While troponin is a critical test, the system’s flexibility also supports other markers of cardiovascular risk and systemic disease like D-Dimer and CRP enabling multiparameter diagnostics at the point of care.